Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study

    August 2026 in “ The Laryngoscope ”
    Rishi Katragadda, Jamil Hayden, Abdul K. Saltagi … Amanda Goslawski
    Studysummary This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Hair Loss Associated With Glucagon-Like Peptide-1 Receptor Agonist Use: A Systematic Review Cureus · 2025
    2. Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review Skin Appendage Disorders · 2025